Ecallantide for treatment of acute attacks of hereditary angioedema

American Journal of Health-System Pharmacy

Volumn 69, Issue 8, 2012, Pages 651-657

  Martelo, Jay L ^a   Woytowish, Melanie R ^b   Chambers, Hannah ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

Author keywords

Angioedemas; Dosage; Ecallantide; Enzyme inhibitors; Mechanism of action; Pharmacokinetics; Toxicity

Indexed keywords

ANDROGEN; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; ESTROGEN; ICATIBANT; KALLIKREIN INHIBITOR; ORAL CONTRACEPTIVE AGENT; OXANDROLONE; PLACEBO; STANOZOLOL; TRANEXAMIC ACID;

ACUTE DISEASE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; AUTOSOMAL DOMINANT DISORDER; DIARRHEA; DISEASE TRANSMISSION; DIZZINESS; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EMOTIONAL STRESS; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INFECTION; INFECTION RISK; INJECTION SITE REACTION; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; VOMITING;

EID: 84860326088     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110227     Document Type: Review

References (27)

1. Davis AE. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol. 1988; 6:595-628.
2. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008; 359:1027-36.
3. Temino VM, Peebles RS. The spectrum and treatment of angioedema. Am J Med. 2008; 121:282-6.
4. Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005; 139:379-94.
5. Bowen T, Cicardi M, Farkas H et al. 2010 International consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010; 6:24.
6. Drugs@FDA. FDA approved drug products search (Berinert). www.access data.fda.gov/scripts/cder/drugsatfda/ (accessed 2010 Dec 12).
7. Shire. FDA approves Shire's Firazyr (icatibant injection) for acute attacks of hereditary angioedema (HAE). www.shire.com/shireplc/en/investors/ irshirenews?id=520 (accessed 2012 Jan 6).
8. Drugs@FDA. FDA approved drug products search (Kalbitor). www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 2010 Dec 12).
9. Zuraw BL, Christiansen SC. New promise and hope for treating hereditary angioedema. Expert Opin Investig Drugs. 2008; 17:697-706.
10. Kalbitor (ecallantide) prescribing information. Cambridge, MA: Dyax Corporation; 2009.
11. Garnock-Jones KP. Ecallantide in acute hereditary angioedema. Drugs. 2010; 70:1423-31.
12. European Medicines Agency. Firazyr prescribing information. www.ema.europa.eu/docs/en-GB/document-library/EPAR - Product-Information/human/ 000899/WC500022966.pdf (accessed 2011 Jul 1).
13. Cicardi M, Gonzalez-Quevedo T, Caballero T et al. DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema. Mol Immunol. 2003; 40:197. Abstract.
14. Schneider L, Lumry W, Vegh A et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007; 120:416-22.
15. Lumry W, Ritchie B, Beck T et al. Interim results of EDEMA2, a multicentre, openlabel, repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema. J Allergy Clin Immunol. 2006; 117:S179. Abstract.
16. Positive final results from EDEMA2 trial with DX-88 for the treatment of hereditary angioedema presented at ACAAI meeting. www.businesswire.com/news/ home/20061114005249/en/Positive-Final-Results-EDEMA2-Trial-DX-88-Treatment (accessed 2010 Dec 28).
17. Limb S. FDA Pulmonary-Allergy Drugs Advisory Committee briefing document: Kalbitor (ecallantide) 30 mg for the treatment of acute attacks of hereditary angioedema. www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4413b1-00-FDA-index. htm (accessed 2010 Dec 28).
18. Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the treatment of acute attacks of hereditary angioedema. N Engl J Med. 2010; 363:523-31.
19. Vernon MK, Rentz AM, Wyrwich KW et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes and changes in symptoms in hereditary angioedema. Qual Life Res. 2009; 18:929-39.
20. Levy RJ, Lumry WR, McNeil DL et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010; 104:523-9.
21. Clinicaltrials.gov. Studies search (Kalbitor). http://clinicaltrials.gov/ ct2/results?term=ecallantide (accessed 2010 Dec 18).
22. Kalbitor important safety information for healthcare professionals, risk evaluation and mitigation strategy (REMS). www.kalbi tor.com/hcp/rems.html (accessed 2011 Jul 1).
23. Medi-Span drug price analysis from PriceRx. Drug search (Kalbitor). www.medispan.com/drug-pricing-analysis-pricerx.aspx (accessed 2011 Apr 12).
24. Berinert (C1 esterase inhibitor, human) prescribing information. Kankakee, IL: CSL Behring; 2009.
25. Kalbitor Access Program. www.kalbitor.com/patient/access-program.html (accessed 2011 Apr 12).
26. Shire. OnePath homepage. www.onepath.com (accessed 2012 Jan 6).
27. Firazyr (icatibant) prescribing information. Lexington, MA: Shire Orphan Therapeutics, Inc.; 2011 Aug.